{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:25:13Z","timestamp":1767356713191,"version":"3.48.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.gastrohep.2025.502528","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T12:34:09Z","timestamp":1752582849000},"page":"502528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-\u03b1 as first- or second-line biologic treatment among patients with ulcerative colitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Francesc","family":"Casellas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Guti\u00e9rrez-Casbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"P. Gisbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"Riestra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Herrera de Guise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Vera-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Mart\u00ednez-Montiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f3nia","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Tagarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Letosa-Abi\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502528_bib0125","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0130","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/ibd\/izy155","article-title":"Effectiveness and safety of vedolizumab in anti-TNF-Na\u00efve patients with inflammatory bowel disease \u2013 a multicenter retrospective European study","volume":"24","author":"Kopylov","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0135","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0140","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","article-title":"Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in Spain: a systematic review","volume":"40","author":"Barreiro-de Acosta","year":"2023","journal-title":"Adv Therapy"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0145","doi-asserted-by":"crossref","first-page":"212505","DOI":"10.7573\/dic.212505","article-title":"Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study)","volume":"7","author":"Mar\u00edn-Jim\u00e9nez","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/07853890.2018.1523550","article-title":"Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis","volume":"50","author":"Brunet","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/MEG.0000000000000226","article-title":"Epidemiology and temporal trends (2000\u20132012) of inflammatory bowel disease in adult patients in a central region of Spain","volume":"26","author":"Lucendo","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/pds.1930","article-title":"Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach","volume":"19","author":"Azevedo","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"Suppl. 3","key":"10.1016\/j.gastrohep.2025.502528_bib0215","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2021","journal-title":"J Crohn's Colitis"},{"year":"2023","series-title":"Entyvio 300mg powder for concentrate for solution for infusion","author":"A\/S TP","key":"10.1016\/j.gastrohep.2025.502528_bib0230"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"year":"2014","series-title":"Takeda Receives European Commission Marketing Authorisation for Entyvio\u00ae (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease","author":"Takeda","key":"10.1016\/j.gastrohep.2025.502528_bib0240"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0245","first-page":"793","article-title":"Vedolizumab as a treatment for Crohn's disease and ulcerative colitis","volume":"10","author":"Ha","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"year":"2020","series-title":"European Commission Approves Subcutaneous Formulation of Entyvio\u00ae (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","author":"Takeda","key":"10.1016\/j.gastrohep.2025.502528_bib0210"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0250","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0255","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-Na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"year":"2023","series-title":"SAS Software \u2013 SAS Analytics Software version 9.4","author":"SAS","key":"10.1016\/j.gastrohep.2025.502528_bib0260"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0265","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ibd\/izad138","article-title":"Real-world effectiveness of vedolizumab vs anti-TNF in biologic-na\u00efve Crohn's disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-study","volume":"30","author":"Bokemeyer","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0270","doi-asserted-by":"crossref","first-page":"480","DOI":"10.5946\/ce.2022.108","article-title":"Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice","volume":"55","author":"Kim","year":"2022","journal-title":"Clin Endosc"},{"key":"10.1016\/j.gastrohep.2025.502528_bib0275","doi-asserted-by":"crossref","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","article-title":"Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohns Colitis 360"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052500398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052500398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:23:28Z","timestamp":1767356608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057052500398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S021057052500398X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502528","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-\u03b1 as first- or second-line biologic treatment among patients with ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502528"}}